PAVmed Inc. (PAVM)

NASDAQ: PAVM · Real-Time Price · USD
0.6385
-0.0399 (-5.87%)
At close: Jun 13, 2025, 4:00 PM
0.6500
+0.0115 (1.80%)
After-hours: Jun 13, 2025, 6:53 PM EDT
-5.87%
Market Cap 11.25M
Revenue (ttm) 1.99M
Net Income (ttm) 72.45M
Shares Out 17.62M
EPS (ttm) 0.96
PE Ratio 0.67
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 156,264
Open 0.6780
Previous Close 0.6784
Day's Range 0.6352 - 0.6780
52-Week Range 0.5500 - 1.9000
Beta 1.06
Analysts Strong Buy
Price Target 19.00 (+2,875.72%)
Earnings Date Aug 11, 2025

About PAVM

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company’s lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, incl... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Apr 28, 2016
Employees 39
Stock Exchange NASDAQ
Ticker Symbol PAVM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for PAVM stock is "Strong Buy" and the 12-month stock price forecast is $19.0.

Price Target
$19.0
(2,875.72% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Long-term strategic partnership and commercial transition follow successful completion of pilot program of Veris Cancer Care Platform™ at OSUCCC – James NEW YORK , June 3, 2025 /PRNewswire/ -- PAVmed ...

11 days ago - PRNewsWire

Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

NEW YORK , May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed I...

Other symbols: LUCD
18 days ago - PRNewsWire

PAVmed Inc. (PAVM) Q1 2025 Earnings Call Transcript

PAVmed Inc. (NASDAQ:PAVM) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Matt Riley - Senior Director of Investor Relations Lishan Aklog - Chairman and Chief Executive ...

4 weeks ago - Seeking Alpha

PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results

Lucid secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash Veris Health completed 1Q25 financing, resumed development of ...

Other symbols: LUCD
4 weeks ago - PRNewsWire

Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results

Processed 3,034 EsoGuard® tests and recognized revenue of $0.8 million in 1Q25 Secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in pro...

Other symbols: LUCD
4 weeks ago - PRNewsWire

PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , May 1, 2025 /PRNewswire/ -- PAVmed Inc.  (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical techno...

Other symbols: LUCD
6 weeks ago - PRNewsWire

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , April 30, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention m...

Other symbols: LUCD
6 weeks ago - PRNewsWire

NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD

Study supports expanded indication and market opportunity for EsoGuard esophageal precancer testing NEW YORK , April 24, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Co...

Other symbols: LUCD
7 weeks ago - PRNewsWire

Lucid Diagnostics Announces Closing of Public Offering of Common Stock

NEW YORK , April 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed...

Other symbols: LUCD
2 months ago - PRNewsWire

Lucid Diagnostics Announces Pricing of Public Offering of Common Stock

NEW YORK , April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed ...

Other symbols: LUCD
2 months ago - PRNewsWire

Lucid Diagnostics Announces Proposed Public Offering of Common Stock

NEW YORK , April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed ...

Other symbols: LUCD
2 months ago - PRNewsWire

Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

NEW YORK , April 3, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed I...

Other symbols: LUCD
2 months ago - PRNewsWire

Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology

Campaign will coincide with Esophageal Cancer Awareness Month and will be featured at the upcoming Digestive Disease Week (DDW) Conference NEW YORK , March 27, 2025 /PRNewswire/ -- Lucid Diagnostics I...

Other symbols: LUCD
2 months ago - PRNewsWire

PAVmed Inc. (PAVM) Q4 2024 Earnings Call Transcript

PAVmed Inc. (NASDAQ:PAVM) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Matt Riley - Senior Director of IR Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Confe...

2 months ago - Seeking Alpha

PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Lucid processed record test volume, saw rapid initial uptake in concierge medicine contracts, and secured first commercial insurance coverage policies  Veris Health secured financing to resume advance...

2 months ago - PRNewsWire

Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Processed a record 4,042 EsoGuard tests in 4Q24, a 45% sequential and 84% annual increase Recognized EsoGuard revenue of $1.2 million in 4Q24   New sales channel generated over 20 new cash-pay concier...

Other symbols: LUCD
2 months ago - PRNewsWire

Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening

Highlights society guidelines recommending non-endoscopic biomarker testing, such as Lucid's EsoGuard Esophageal DNA Test, as an acceptable alternative to endoscopy NEW YORK , March 20, 2025 /PRNewswi...

Other symbols: LUCD
3 months ago - PRNewsWire

Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

Study confirms clinical utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy NEW YORK , March 18, 2025 /PRNewswire/ -- Lucid Diagnosti...

Other symbols: LUCD
3 months ago - PRNewsWire

Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test

Regional Blue Cross Blue Shield plan will cover non-invasive screening of esophageal precancer and cancer NEW YORK , March 13, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or ...

Other symbols: LUCD
3 months ago - PRNewsWire

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , March 10, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention me...

Other symbols: LUCD
3 months ago - PRNewsWire

Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering

NEW YORK , March 5, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed...

Other symbols: LUCD
3 months ago - PRNewsWire

Lucid Diagnostics Announces $15.3 Million Registered Direct Offering

NEW YORK , March 4, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed...

Other symbols: LUCD
3 months ago - PRNewsWire

Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD

Lucid to support study of this expanded indication for esophageal precancer testing in partnership with NIH investigators NEW YORK , Feb. 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD...

Other symbols: LUCD
3 months ago - PRNewsWire

Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement

NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed ...

Other symbols: LUCD
3 months ago - PRNewsWire

PAVmed and Subsidiary Veris Health Complete Private Placement Financing

Gross proceeds of approximately $2.4 million from sale of PAVmed securities priced at-the-market and Veris common stock priced at a $35 million pre-money valuation NEW YORK , Feb. 24, 2025 /PRNewswire...

3 months ago - PRNewsWire